Myasthenia Gravis Market - Global Industry Analysis

Myasthenia Gravis Market by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), by Treatment (Surgery, Medication, Plasmapheresis and Intravenous Immunoglobulin, Autologous Hematopoietic Stem Cell Transplantation (HSCT), and others), and by End-User (Hospitals, Academic Research Institutes, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 18-Mar-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3927 Status : Published

Global myasthenia gravis market expected to generate around USD 2,091 million by 2025, at a CAGR of around 10.2% between 2019 and 2025. Myasthenia Gravis is an autoimmune neuromuscular disorder that leads to serious muscle weakness. It is caused due to an error in the transmission of nerve impulses to muscles.

Description

The report covers a forecast and an analysis of the myasthenia gravis market on a global and regional level. The study provides historical data for 2016, 2017, and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the myasthenia gravis market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the myasthenia gravis market on a global level.

In order to give the users of this report a comprehensive view of the myasthenia gravis market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Myasthenia Gravis Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the myasthenia gravis market based on diagnosis, treatment, end-user, and region. All the segments have been analyzed based on present and future trends in the market are estimated from 2019 to 2025. By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, Brazil, China, Japan, India, and Brazil.

Some key players of the global myasthenia gravis market are Novartis Pharmaceuticals Corporation, AbbVie Inc., Biogen Inc., Pfizer, Valeant Pharmaceuticals International, Bristol-Myers Squibb Company, F. Hoffmann Roche La Ltd., GlaxoSmithKline, RPG Life Sciences, and Grifols SA, among others.

This report segments the global myasthenia gravis market as follows:

Global Myasthenia Gravis Market: Diagnosis Analysis

  • Edrophonium Tests
  • Blood Tests
  • Pulmonary Function Tests
  • Electrodiagnostic
  • Imaging
  • Others

Global Myasthenia Gravis Market: Treatment Analysis

  • Surgery
  • Medication
  • Plasmapheresis and Intravenous Immunoglobulin
  • Autologous Hematopoietic Stem Cell Transplantation (HSCT)
  • Others

Global Myasthenia Gravis Market: End-User Analysis

  • Hospitals
  • Academic Research Institutes
  • Clinics
  • Other

Global Myasthenia Gravis Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Myasthenia Gravis Market, 2016-2025 (USD Million)
    • 2.2. Global Myasthenia Gravis Market: Snapshot
  •  
  • Chapter 3. Myasthenia Gravis Market - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Myasthenia Gravis market drivers: Impact analysis
      • 3.2.2. Increased prevalence of myasthenia gravis
      • 3.2.3. Rising adoption of novel therapies
    • 3.3. Market Restraints
      • 3.3.1. Global Myasthenia Gravis market restraints: Impact analysis
      • 3.3.2. High treatment costs
      • 3.3.3. Limited availability of FDA-approved drugs
    • 3.4. Opportunities
      • 3.4.1. Research and development activities
      • 3.4.2. Increasing investment
    • 3.5. Porter's Five Forces analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Diagnosis
      • 3.6.2. Market attractiveness analysis, by Treatment
      • 3.6.3. Market attractiveness analysis, by End-User
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Myasthenia Gravis Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Myasthenia Gravis Market: company market share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. R&D
      • 4.2.5. Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Technology Portfolio
  •  
  • Chapter 5. Global Myasthenia Gravis Market - Diagnosis Analysis
    • 5.1. Global Myasthenia Gravis Market: Diagnosis overview
      • 5.1.1. Global Myasthenia Gravis market revenue share, by Diagnosis, 2018 and 2025
    • 5.2. Edrophonium Tests
      • 5.2.1. Global Edrophonium Tests Market, 2016-2025 (USD Million)
    • 5.3. Blood Tests
      • 5.3.1. Global Blood Tests Market, 2016-2025 (USD Million)
    • 5.4. Pulmonary Function Tests
      • 5.4.1. Global Pulmonary Function Tests Market, 2016-2025 (USD Million)
    • 5.5. Electrodiagnostic
      • 5.5.1. Global Electrodiagnostic Market, 2016-2025 (USD Million)
    • 5.6. Imaging
      • 5.6.1. Global Imaging Market, 2016-2025 (USD Million)
    • 5.7. Others
      • 5.7.1. Global Others Market, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Myasthenia Gravis Market - Treatment Analysis
    • 6.1. Global Myasthenia Gravis: Treatment overview
      • 6.1.1. Global Myasthenia Gravis Market revenue share, by Treatment, 2018 and 2025
    • 6.2. Surgery
      • 6.2.1. Global Surgery Market, 2016-2025 (USD Million)
    • 6.3. Medication
      • 6.3.1. Global Medication Market, 2016-2025 (USD Million)
    • 6.4. Plasmapheresis and Intravenous Immunoglobulin
      • 6.4.1. Global Plasmapheresis and Intravenous Immunoglobulin Market, 2016-2025 (USD Million)
    • 6.5. Autologous Hematopoietic Stem Cell Transplantation (HSCT)
      • 6.5.1. Global Autologous Hematopoietic Stem Cell Transplantation (HSCT) Market, 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Others Market, 2016-2025 (USD Million)
  •  
  • Chapter 7. Global Myasthenia Gravis Market - End-User Analysis
    • 7.1. Global Myasthenia Gravis Market: End-User overview
      • 7.1.1. Global Myasthenia Gravis Market revenue share, by End-User, 2018 and 2025
    • 7.2. Hospitals
      • 7.2.1. Global Hospitals Market, 2016-2025 (USD Million)
    • 7.3. Academic Research Institutes
      • 7.3.1. Global Academic Research Institutes Market, 2016-2025 (USD Million)
    • 7.4. Clinics
      • 7.4.1. Global Clinics Market, 2016-2025 (USD Million)
    • 7.5. Others
      • 7.5.1. Global Others Market, 2016-2025 (USD Million)
  •  
  • Chapter 8. Global Myasthenia Gravis Market - Regional Analysis
    • 8.1. Global Myasthenia Gravis Market: Regional overview
      • 8.1.1. Global Myasthenia Gravis Market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
      • 8.2.2. North America Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
      • 8.2.3. North America Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.2.4.2. The U.S. Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.2.4.3. The U.S. Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.2.5.2. Rest of North America Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.2.5.3. Rest of North America Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
      • 8.3.2. Europe Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
      • 8.3.3. Europe Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.3.4.2. Germany Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.3.4.3. Germany Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.3.5. France
        • 8.3.5.1. France Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.3.5.2. France Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.3.5.3. France Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.3.6. UK
        • 8.3.6.1. UK Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.3.6.2. UK Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.3.6.3. UK Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.3.7.3. Rest of Europe Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.4.4.2. China Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.4.4.3. China Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.4.5.2. Japan Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.4.5.3. Japan Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.4.6.2. India Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.4.6.3. India Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
      • 8.5.2. Latin America Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
      • 8.5.3. Latin America Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.5.4.2. Brazil Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.5.4.3. Brazil Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Myasthenia Gravis market revenue, by Diagnosis, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Myasthenia Gravis market revenue, by Treatment, 2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Myasthenia Gravis market revenue, by End-User, 2016-2025 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Novartis Pharmaceuticals Corporation
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Diagnosis portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. AbbVie Inc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Diagnosis portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Biogen Inc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Diagnosis portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Pfizer
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Diagnosis portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Valeant Pharmaceuticals International
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Diagnosis portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Bristol-Myers Squibb Company
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Diagnosis portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. F. Hoffmann Roche La Ltd.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Diagnosis portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. GlaxoSmithKline
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Diagnosis portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. RPG Life Sciences
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Diagnosis portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Grifols SA
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Diagnosis portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments

Table Of Figures

List of Figures 

1. Market research process
2. Market research methodology
3. Global Myasthenia Gravis market revenue, 2016–2025 (USD Million)
4. Porter’s Five Forces Analysis
5. Myasthenia Gravis market attractiveness analysis, by Diagnosis
6. Myasthenia Gravis Market: Market attractiveness analysis, by Treatment
7. Myasthenia Gravis market: Market attractiveness analysis, by End-User
8. Myasthenia Gravis Market: Market attractiveness analysis, by Region
9. Company market share analysis, 2018
10. Global Myasthenia Gravis market revenue share by Diagnosis, 2018 and 2025
11. Global Edrophonium Tests market, 2016–2025 (USD Million)
12. Global Blood Tests market, 2016–2025 (USD Million)
13. Global Pulmonary Function Tests market, 2016–2025 (USD Million)
14. Global Electrodiagnostic market, 2016–2025 (USD Million)
15. Global Imaging market, 2016–2025 (USD Million)
16. Global Others market, 2016–2025 (USD Million)
17. Global Myasthenia Gravis market revenue share by Treatment, 2018 and 2025
18. Global Surgery market, 2016–2025 (USD Million)
19. Global Medication market, 2016–2025 (USD Million)
20. Global Plasmapheresis and Intravenous Immunoglobulin market, 2016–2025 (USD Million)
21. Global Autologous Hematopoietic Stem Cell Transplantation (HSCT) market, 2016–2025 (USD Million)
22. Global Others market, 2016–2025 (USD Million)
23. Global Myasthenia Gravis market revenue share by End-User, 2018 and 2025
24. Global Hospitals market, 2016–2025 (USD Million)
25. Global Academic Research Institutes market, 2016–2025 (USD Million)
26. Global Clinics market, 2016–2025 (USD Million)
27. Global Others market, 2016–2025 (USD Million)


Table Of Tables

List of Tables

1. Myasthenia Gravis: Market Snapshot                                                            
2. Drivers of global Myasthenia Gravis market: Impact analysis 
3. Restraints of global Myasthenia Gravis market: Impact analysis
4. North America Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
5. North America Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
6. North America Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
7. The U.S. Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
8. The U.S. Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
9. The U.S. Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
10. Rest of North America Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
11. Rest of North America Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
12. Rest of North America Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
13. Europe Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
14. Europe Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
15. Europe Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
16. UK Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
17. UK Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
18. UK Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
19. Germany Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
20. Germany Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
21. Germany Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
22. France Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
23. France Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
24. France Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
25. Rest of Europe Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
26. Rest of Europe Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
27. Rest of Europe Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
28. Asia Pacific Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
29. Asia Pacific Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
30. Asia Pacific Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
31. China Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
32. China Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
33. China Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
34. Japan Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
35. Japan Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
36. Japan Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
37. India Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
38. India Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
39. India Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
40. Rest of Asia Pacific Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
41. Rest of Asia Pacific Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
42. Rest of Asia Pacific Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
43. Latin America Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
44. Latin America Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
45. Latin America Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
46. Brazil Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
47. Brazil Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
48. Brazil Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
49. Rest of Latin America Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
50. Rest of Latin America Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
51. Rest of Latin America Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)
52. The Middle East and Africa Myasthenia Gravis market revenue, by Diagnosis, 2016–2025 (USD Million)
53. The Middle East and Africa Myasthenia Gravis revenue, by Treatment, 2016–2025 (USD Million)
54. The Middle East and Africa Myasthenia Gravis market revenue, by End-User type, 2016–2025 (USD Million)

Methodology

Free Analysis

Myasthenia Gravis is an autoimmune neuromuscular disorder that leads to serious muscle weakness. It is caused due to an error in the transmission of nerve impulses to muscles. It generally occurs when the normal communication between nerve and muscle disrupts at the neuromuscular joints. In this disorder, the antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint, which, in turn, prevents the muscles from contracting and performing normal functions. There is no permanent cure for this condition and it affects one’s quality of life. The treatment helps in the improvement of the quality of life and life expectancy remains normal. The skeletal muscle weakness leads to the drooping eyelids, double vision, trouble in talking, walking trouble, etc. It mostly affects the eyes and facial muscles along with the gastrointestinal tract. The enlargement of the thymus or the development of thymoma can also be observed in myasthenia gravis patients. It can be diagnosed with the help of a blood test, nerve conduction test, and edrophonium test. Its treatment option includes the removal of thymus gland and medications, such as acetylcholinesterase inhibitors, immunosuppressant, etc.

As per the Myasthenia Gravis Foundation of America 2015, there were around 14 to 20 myasthenia gravis cases per 100,000 people, approximating nearly 36,000 to 60,000 cases of myasthenia gravis in the U.S. Furthermore, an increase in the number of autoimmune disorders coupled with strong product pipeline is also expected to drive the growth of the global myasthenia gravis market over the estimated period. The increase in healthcare expenditure, robust healthcare infrastructure, and growth in the awareness about the ailment among people is also anticipated to drive the growth of the global myasthenia gravis market. Moreover, increased adoption of novel therapies along with favorable reimbursement policies in developed economies will promote the myasthenia gravis market globally. Increased research and development activities and massive investments are expected to create new growth opportunities in the myasthenia gravis market. However, the high treatment costs, limited availability of FDA-approved drugs may inhibit the growth of the myasthenia gravis market in the future.

Global Myasthenia Gravis Market

The global myasthenia gravis market is segmented on the basis of treatment, diagnosis, and end-user. By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Blood tests are expected to hold the major market share. By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. The medication segment is expected to contribute majorly toward the global market over the forecast timespan. By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others. Hospitals are expected to hold the major market share in the future.

North America is expected to lead the global myasthenia gravis market over the forecast time period due to the increased adoption of novel therapies, increase in awareness among the people, favorable reimbursement policies, the presence of developed countries, such as the U.S. and Canada, and robust healthcare infrastructure. Europe is expected to be the second largest market over the forecast time period and closely follow North America in terms of revenue. Asia Pacific is expected to grow rapidly over the forecast time period, owing to the presence of developing economies such, as India and China, the presence of strong healthcare infrastructure, increased affordability, and substantial technological advancements.

Some key players of the global myasthenia gravis market are Novartis Pharmaceuticals Corporation, AbbVie Inc., Biogen Inc., Pfizer, Valeant Pharmaceuticals International, Bristol-Myers Squibb Company, F. Hoffmann Roche La Ltd., GlaxoSmithKline, RPG Life Sciences, and Grifols SA, among others.

Choose License Type

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed